Intraperitoneal administration of dual immune checkpoint inhibitor therapy in recurrent gynecologic malignancies: Updated results of a phase 1b study
Anne Knisely(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Steven Y. Huang(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Jolyn Taylor, Sara Hull(The University of Texas MD Anderson Cancer Center), Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Rahul A. Sheth(Massachusetts General Hospital), Kathleen M. Schmeler(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Kathryn Lito(The University of Texas MD Anderson Cancer Center), Ann Mosley(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Karen Lu(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation
|Cell|2019|312
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
|JNCI Journal of the National Cancer Institute|2002|285